International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma

NCT06839703 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

High-risk GD2-Positive Ewing Sarcoma

Interventions

DRUG: Dinutuximab beta

Sponsor

Prof. Dr. Dirk Reinhardt